The US Court of Appeals for the Federal Circuit has upheld that the Myriad Genetics composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible material under Section 101 of the US Patent Act.
According to the company, the verdict reiterates the Court's earlier decision rendered on 29 July 2011.
Myriad Genetics president and CEO Peter Meldrum said Myriad Genetics is pleased with the favorable decision the Court rendered, which again confirmed that isolated DNA is patentable.
"Importantly, the Court agreed with Myriad that isolated DNA is a new chemical matter with important utilities which can only exist as the product of human ingenuity," Meldrum added.
The US Court of Appeals has reviewed its earlier judgment following a directive from the country's apex court.
Myriad Genetics is a US based company that develops and markets molecular diagnostic tests for diseases like diabetes, depression, and rheumatoid arthritis and its product portfolio includes BRACAnalysis, Colaris, Melaris, Panexia, OnDose.